Publication
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
Authors not recorded
Cancer Cell2010PMID 20227043PMC2897158stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Ovarian Neoplasmcivic_curation1.00
- drugSeribantumabcivic_curation1.00
- geneNRG1civic_curation1.00
- variantNRG1 Expressioncivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20227043
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRG1 Expression1 | ||||||||
| Seribantumab | Malignant Ovarian Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID778An NRG1-ERBB3 autocrine signal-transducing loop was identified in a subset of ovarian cancers and cell lines. Disruption of this loop led to decreased cell-growth in-vitro and prolonged survival in-vi… (full text at CIViC) PMID 20227043 · Sheng et al., 2010 · Open in CIViC | civic |